Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.4M | $4.48M | $44.5M | $59.3M | $109M | $149M | $120M | $117M | $179M | $294M |
| Revenue growth | — | -78.0% | 892.6% | 33.2% | 83.2% | 37.4% | -19.4% | -2.8% | 53.4% | 64.1% |
| Operating income | -$69.7M | -$79.6M | -$72.7M | -$69.1M | -$29.0M | -$12.5M | -$55.5M | -$20.5M | $24.2M | $125M |
| Operating margin | -342.2% | -1775.6% | -163.3% | -116.5% | -26.7% | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% |
| Net income | -$69.2M | -$78.0M | -$70.5M | -$66.9M | -$29.7M | -$17.9M | -$58.6M | -$25.1M | $17.5M | $367M |
| Net margin | -339.6% | -1739.3% | -158.3% | -112.8% | -27.4% | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% |
| EPS (diluted) | -$0.73 | -$0.62 | -$0.44 | -$0.40 | -$0.18 | -$0.11 | -$3.44 | -$1.44 | $0.99 | $19.48 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75.9M | -$77.6M | -$58.8M | -$41.5M | -$52.2M | $5.88M | -$73.8M | -$5.74M | $31.5M | $75.7M |
| Capital expenditures | $804K | $164K | $1.11M | $1.46M | $1.26M | $627K | $450K | — | — | — |
| Free cash flow | -$76.7M | -$77.7M | -$59.9M | -$43.0M | -$53.4M | $5.25M | -$74.2M | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17.6M | $38.3M | $76.3M | $22.5M | $30.4M | $18.9M | $24.5M | $32.8M | $56.7M | $40.6M |
| Total assets | $78.1M | $119M | $139M | $148M | $110M | $167M | $134M | $117M | $164M | $514M |
| Total liabilities | — | — | — | — | — | $137M | $148M | $146M | $161M | $122M |
| Long-term debt | — | — | — | $10.0M | $20.0M | $20.0M | $40.0M | $60.0M | $60.0M | $52.5M |
| Shareholders' equity | $55.0M | $101M | $110M | $53.8M | $34.0M | $30.4M | -$13.6M | -$28.6M | $3.29M | $391M |
| Retained earnings | -$1.06B | -$1.14B | -$1.21B | -$1.28B | -$1.31B | -$1.32B | -$1.38B | -$1.41B | -$1.39B | -$1.02B |
| Shares (wtd avg diluted) | 99.3M | 147M | 167M | 167M | 169M | 170M | 17.0M | 17.4M | 17.7M | 18.8M |
Every figure is extracted from RIGEL PHARMACEUTICALS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.